Author Contributions: Dr Bansal and Dr Ridker had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Bansal, Mora, Ridker.
Acquisition of data: Buring, Rifai, Ridker.
Analysis and interpretation of data: Bansal, Mora, Sacks, Ridker.
Drafting of the manuscript: Bansal, Ridker.
Critical revision of the manuscript for important intellectual content: Bansal, Buring, Rifai, Mora, Sacks, Ridker.
Statistical analysis: Bansal, Mora.
Obtained funding: Buring, Ridker.
Administrative, technical, or material support: Rifai, Ridker.
Study supervision: Ridker.
Financial Disclosures: Dr Buring reported receiving investigator-initiated research funding and support as principal investigator from the National Institutes of Health (the National Heart, Lung, and Blood Institute, the National Cancer Institute, and the National Institute of Aging) and Dow Corning Corporation; research support for pills, packaging, or both from Bayer Heath Care and the Natural Source Vitamin E Association; and honoraria from Bayer for speaking engagements. Dr Rifai reported receiving grant support from Merck Research Laboratories; serving as a consultant to Merck Research Laboratories and Sanofi-Aventis; and receiving honoraria for speaking from Abbott Laboratories, Dade Behring, Denka Seiken, Merck Research Laboratories, Ortho Diagnostics, and Roche Diagnostics. Dr Sacks reported that he currently or in the past 5 years has received fees for consultation or lecturing on diagnosis, drug development, or treatment of hyperlipidemia from Abbott, Aegerion, Bristol-Myers Squibb, Celera Diagnostics, Fournier, Johnson & Johnson, Kos, Lilly, Lipid Sciences, Merck, Pfizer, Quest Diagnostics, Sanofi-Aventis, and Solvay; he also reported receiving expert testimony fees related to hyperlipidemia treatment from Kos and Pfizer, and being a stockholder in Lipid Sciences. Dr Ridker reported that he currently or in the past 5 years has received research funding support from multiple not-for-profit entities including the American Heart Association, the Doris Duke Charitable Foundation, the Leducq Foundation, the National Cancer Institute, the National Heart, Lung, and Blood Institute, the Donald W. Reynolds Foundation, and the James and Polly Annenberg La Vea Charitable Trusts; that currently or in the past 5 years he has received investigator-initiated research support from for-profit entities including Abbott, AstraZeneca, Bayer, Bristol-Myers Squibb, Dade-Behring, Novartis, Pharmacia, Roche, and Sanofi-Aventis; and that he is listed as a coinventor on patents held by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and has served as a consultant to AstraZeneca, Dade-Behring, Isis Pharmaceutical, Sanofi-Aventis, and Schering-Plough. No other disclosures were reported.
Funding/Support: This study was supported by grants from the Donald W. Reynolds Foundation (Las Vegas, Nevada) and the Leducq Foundation (Paris, France) and by grant T32 HL007575-21 from the National Heart, Lung, and Blood Institute, with additional support from Abbott Laboratories (Abbott Park, Illinois). The Women's Health Study was funded by grant HL-43851 from the National Heart, Lung, and Blood Institute and grant CA-47988 from the National Cancer Institute.
Role of the Sponsor: The funding agencies played no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.
Additional Contributions: We thank the participants, staff, and investigators of the Women's Health Study for their valuable contributions.